Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.

Botticelli A, Zizzari I, Mazzuca F, Ascierto PA, Putignani L, Marchetti L, Napoletano C, Nuti M, Marchetti P.

Oncotarget. 2017 Jan 31;8(5):8890-8899. doi: 10.18632/oncotarget.12985. Review.

2.

Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.

Asmar N, Ibrahim T, Rey JF.

Dig Dis Sci. 2018 Sep;63(9):2177-2179. doi: 10.1007/s10620-018-5188-z. No abstract available.

PMID:
29982987
3.

PDL-1/PD1 inhibitors: antibody or antinobody?

Aoun F, Rassy EE, Assi T, Kattan J.

Future Oncol. 2017 Aug;13(19):1669-1671. doi: 10.2217/fon-2017-0215. Epub 2017 Aug 23. No abstract available.

PMID:
28831825
4.

Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.

Patel J, Crawford JM.

Biochemistry. 2018 Feb 13;57(6):901-903. doi: 10.1021/acs.biochem.7b01249. Epub 2018 Jan 19. No abstract available.

PMID:
29350031
5.

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Aspeslagh S, Matias M, Palomar V, Dercle L, Lanoy E, Soria JC, Postel-Vinay S.

Eur J Cancer. 2017 Dec;87:65-74. doi: 10.1016/j.ejca.2017.09.027. Epub 2017 Nov 7.

PMID:
29126088
6.

[The "immune checkpoints", how does it work].

Granier C, Soumelis V, Mandavit M, Gibault L, Belazzoug R, de Guillebon E, Badoual C, Tartour E, Roussel H.

Ann Pathol. 2017 Feb;37(1):18-28. doi: 10.1016/j.annpat.2016.12.007. Epub 2017 Feb 1. French.

PMID:
28160999
7.
8.

[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].

Duruisseaux M, Lize-Dufranc C, Badoual C, Bibeau F.

Ann Pathol. 2017 Feb;37(1):46-54. doi: 10.1016/j.annpat.2016.12.016. Epub 2017 Jan 26. Review. French.

PMID:
28131419
9.

Hyperprogressive disease with anti-PD-1 and anti-PD-L1.

Brower V.

Lancet Oncol. 2016 Dec;17(12):e527. doi: 10.1016/S1470-2045(16)30590-3. Epub 2016 Nov 18. No abstract available.

PMID:
27866860
10.

Atypical autoimmune adverse effects with checkpoint blockade therapies.

Friedman CF, Snyder A.

Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658. No abstract available.

PMID:
27993802
11.

Inhibitors of the PD-1 Pathway in Tumor Therapy.

LaFleur MW, Muroyama Y, Drake CG, Sharpe AH.

J Immunol. 2018 Jan 15;200(2):375-383. doi: 10.4049/jimmunol.1701044. Review.

12.

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C.

Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18.

PMID:
28826073
13.

Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.

Cousin S, Italiano A.

Clin Cancer Res. 2016 Sep 15;22(18):4550-5. doi: 10.1158/1078-0432.CCR-15-2569. Epub 2016 Jul 19. Review.

15.

Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O.

Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Review.

PMID:
26765102
16.

Biomarkers of response to PD-1/PD-L1 inhibition.

Maleki Vareki S, Garrigós C, Duran I.

Crit Rev Oncol Hematol. 2017 Aug;116:116-124. doi: 10.1016/j.critrevonc.2017.06.001. Epub 2017 Jun 9. Review.

17.

Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?

Yang HY, Sun LJ, Mao YL.

Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):93-94. doi: 10.1016/j.hbpd.2018.03.001. Epub 2018 Mar 8. No abstract available.

PMID:
29576280
18.

Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Mitsuhashi A, Okuma Y.

Clin Transl Oncol. 2018 Aug;20(8):966-974. doi: 10.1007/s12094-017-1827-7. Epub 2018 Jan 8. Review.

PMID:
29313208
19.

Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.

Einstein DJ, McDermott DF.

Clin Adv Hematol Oncol. 2017 Jun;15(6):478-488. Review.

PMID:
28749908
20.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD.

Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14. Review. Erratum in: Ann Oncol. 2016 Jul;27(7):1362.

PMID:
26371282

Supplemental Content

Support Center